The discovery of an important somatic mutation in MPN, an activating mutation in the Janus kinase 2 domain (JAK2 V617F) of the erythropoietin (EPO) receptor contributed to the understanding of the pathophysiology, pathogenesis and molecular biology of MPN. The gene discussed is EPO; the disease is myeloproliferative neoplasm.